In short
Palopegteriparatide, also known as TransCon PTH, is an investigational parathyroid hormone (PTH) replacement therapy being studied for adult patients with hypoparathyroidism. This article explores the expanded access program for this promising treatment, designed for patients who have previously received PTH treatment and have an unmet medical need that cannot be addressed by existing commercial products or clinical trials.
At a glance
- Drug Name
- Palopegteriparatide (TransCon PTH)
- Condition Treated
- Hypoparathyroidism
- Program Type
- Expanded Access Program
- Eligible Patients
- Adults with hypoparathyroidism, previously received PTH treatment, with unmet medical needs
- Administration Method
- Subcutaneous injection via prefilled pen
- Dosing Strategy
- Fixed initial dose, followed by individual titration based on serum calcium levels
- Impact on Current Treatments
- Conventional therapies (calcium, vitamin D) may be reduced or discontinued
- Program Duration
- Until Palopegteriparatide becomes commercially available to the participant
What is Palopegteriparatide?
Palopegteriparatide, also known as TransCon PTH, is an investigational drug being developed to treat hypoparathyroidism. It is a new form of parathyroid hormone (PTH) replacement therapy that aims to address the unmet medical needs of patients with this condition.
What is Hypoparathyroidism?
Hypoparathyroidism is a rare condition where the body doesn't produce enough parathyroid hormone. This hormone is crucial for regulating calcium levels in the body. When there's not enough of it, it can lead to low calcium levels, which can cause various symptoms and health issues.
How Palopegteriparatide Works
Palopegteriparatide is designed to replace the missing parathyroid hormone in patients with hypoparathyroidism. By doing so, it aims to help regulate calcium levels in the body more effectively than current standard treatments, which often involve taking calcium and vitamin D supplements.
Administration and Dosage
Palopegteriparatide is administered as a subcutaneous injection, which means it's injected just under the skin. The drug comes in a single-patient-use prefilled pen, making it potentially easier for patients to use at home. Each pen contains a solution with a concentration of 0.3 mg PTH(1-34)/mL.
Expanded Access Program
An Expanded Access Program is currently available for palopegteriparatide. This program is designed for adult patients with hypoparathyroidism who meet specific criteria:
- Have previously received PTH treatment
- Are not eligible for ongoing TransCon PTH clinical trials
- Have a clear unmet medical need that cannot be adequately treated by a commercial product or a clinical trial
Patients in this program start with a fixed dose of the drug, which is then gradually adjusted to find the optimal dose based on their serum calcium levels. This individualized approach aims to provide the best possible treatment for each patient.
Potential Benefits
While palopegteriparatide is still under investigation, it may offer several potential benefits for patients with hypoparathyroidism:
- More effective hormone replacement: As a form of PTH replacement therapy, it may more closely mimic the body's natural hormone function.
- Reduced need for supplements: Patients may be able to reduce or discontinue their calcium and vitamin D supplements as they adjust to palopegteriparatide.
- Convenient administration: The prefilled pen design could make it easier for patients to administer their treatment at home.
- Individualized treatment: The program allows for dose adjustment based on each patient's needs and response to the treatment.
It's important to note that as an investigational drug, palopegteriparatide is still being studied, and more research is needed to fully understand its effectiveness and potential side effects.